QuikRead go wrCRP

Accurate measurement of C-reactive protein (CRP) can be critical in the management of a patient with symptoms of an infection. The QuikRead go wrCRP test helps to identify patients who benefit from antibiotics and it is valuable in monitoring the treatment outcome. The easy-to-use QuikRead go wrCRP test can be used near the patient and it provides immediate wrCRP result

A wide range CRP test allows the extension of CRP values from conventional use to testing e.g neonatal sepsis¹ as well as to predict disease severity in COPD² and aid in cardiovascular risk assessment³. Room temperature storage for unopened kit and small sample volume ease the everyday work flow.

QuikRead go wrCRP is an efficient tool for point-of-care settings to guide the treatment decisions of healthcare professionals.

QuikRead go wrCRP provides you with

Kit storage at room temperature up to 25°C

• Easy to store in the healthcare unit
• Enables immediate use, no need to warm up reagents

Wide measuring range

• Offers wide CRP result from whole blood samples from 0.5 up to 200 mg/l and plasma/serum samples from 0.5 up to 120 mg/l
• Enables using CRP in wide range of indications

Small sample volume 10 µl

• Sample collection is easy
• Improved convenience for the patient

Fast point-of-care CRP test

• Measurement time only 2 minutes

Easy to use

• Fully automatic testing procedure

Connectivity

• QuikRead go instrument is connectable to most HIS and LIS systems

Test results should never be used alone, without a complete clinical evaluation.

QuikRead go wrCRP is not registered in the USA.

References:

1. Hengst JM: The role of C-reactive protein in the evaluation and management of infants with suspected sepsis. Adv Neonatal Care 2003; 3:3–13. https://doi.org/10.1053/adnc.2003.50010
2. Mendy A, Forno E, Niyonsenga T, Gasana J. Clin Respir J. 2017. Blood biomarkers as predictors of long-term mortality in COPD. https://doi.org/10.1111/crj.12752
3. Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Emerging Risk Factors Collaboration. 2010 Lancet 375(9709):132-40. https://doi.org/10.1016/S0140-6736(09)61717-7

Regular use of QuikRead go CRP Controls is recommended.

Recommended Controls:

• 153764 QuikRead go CRP Control (~25 mg/l with blue colour)
• 153763 QuikRead go CRP Control High (~75 mg/l with blue colour)
• 153765 QuikRead go CRP Control Low (~2.5 mg/l with blue colour)

Optional Controls:

• 153038 QuikRead go wrCRP Control (~30 mg/l)
• 153039 QuikRead go wrCRP Control High (~80 mg/l)
• 68257 Ultrasensitive CRP Control (~3 mg/l)

• normally present in very low concentrations in the blood of healthy people; 99% have levels of <10 mg/l ¹ and 90 % have levels < 3 mg/l².
• after birth concentrations are very low (0,1 mg/l) and there is a physiological rise during the first days of life (to approx. 2 mg/l)³
• uncomplicated viral infections mostly induce (with some exceptions) a very modest elevation or none at all¹
• in bacterial infections, concentrations increase markedly¹
• elevated concentrations can be detected within 6 - 12 h after onset of an inflammatory stimulus, reaching maximum within 24 - 48 h^{4, 5}
• rise in concentrations corresponds to severity of infection¹
• concentrations fall rapidly when the patient responds to antibiotic treatment¹
• normalisation of the concentration may indicate that the duration of the treatment has been sufficient and the treatment can be discontinued^{1, 6, 7}
• in a big part of septic neonates the concentrations are below 6 mg/l ^{8, 9, 10}

References:

1. Pepys MB. The acute phase response and C-reactive protein. In: Warrell DA, Cox TM, Firth JD, Benz EJ, eds. Oxford Textbook of Medicine, 4th ed. Oxford University Press, 2003. Vol 2, p.150 - 156.
2. Shine, B., de Beer, FC., Pepys, MB. Solid phase radioimmunoassays for C-reactive protein. Clin Chim Acta, 1981,117: 13 - 23.
3. Chiesa, C., Natale, F., Pascone, R., Osborn, JF., Pacifico, L., Bonci, E., De Curtis, M. C reactive protein and procalcitonin: Reference intervals for preterm and term newborns during the early neonatal period. Clinica Chimica Acta, 2011, 412: 1053 - 1059.
4. Bjerrum L. C-reactive protein measurement in general practice may lead to lower antibiotic prescribing for sinusitis. Br J Gen Pract 2004; 54: 659 - 662.
5. Pepys MB. C-reactive protein fifty years on. Lancet 1981; 1: 653 - 657.
6. Philip AGS, Mills PC. Use of C-reactive Protein in Minimizing Antibiotic Exposure: Experience With Infants Initially Admitted to a Well-Baby Nursery. Pediarics 2000; 106.
7. Ehl S et al. C-Reactive Protein Is a Useful Marker for Guiding Duration of Antibiotic Therapy in Suspected Neonatal Bacterial Infection. Pediatrics 1997; 99: 216 - 221.
8. Hofer, N., Müller, W., Resch, B.Non-infectious conditions and gestational age influence C-reactive protein values in newborns during the first 3 days of life. Clin Chem Lab Med, 2011,49: 297 - 302.
9. Wasunna, A., Whitelaw, A., Gallimore, R., Hawkins, PN., Pepys, MB. C-reactive protein and bacterial infection in preterm infants. Eur J Pediatr, 1990, 149: 424 - 427.
10. Mathers, NJ., Pohlandt, F. Diagnostic audit of C-reactive protein in neonatal infection. Eur J Pediatr, 1987, 146: 147 - 151.

Antibiotics are a cornerstone of the management of bacterial infections. 80 - 90% of antibiotics are prescribed in primary care, and up to 80% of these are used to treat acute respiratory tract infections¹. It is estimated that approximately 50% of all antibiotic prescriptions are unnecessary². Although most of both upper and lower respiratory tract infections are self-limiting and caused by viruses, antibiotics are frequently used to treat these conditions. Unnecessary and inappropriate use of antibiotics favours the emergence and spread of resistant bacteria. Antibiotic resistance is a major public health concern, which could cause harm to a large number of patients worldwide if infections are no longer susceptible to common medicines used to treat them. Therefore, antibiotics should be used with caution and only when necessary³.

The use of antibiotics in primary care varies considerably between countries, which is unlikely to be caused by differences in the frequency of bacterial infections. There is a clear correlation between the use of antibiotics and the emergence of antibiotic resistance^4-6. As stated by the World Health Organization (WHO)³, restricting an inappropriate and excessive antibiotic use is important to slow down or even reverse the development of antibiotic resistance.

The QuikRead go CRP test helps healthcare professionals to identify those patients who need - and particularly those who do not need - antibiotic therapy. It is also important to know whether the antibiotics will affect the course of the illness^7,8. QuikRead go CRP is useful for following up the effect of treatment. With accurate information, patients can be more easily reassured that symptomatic treatment will be sufficient. On the other hand, a high QuikRead go CRP reading would suggest a bacterial infection requiring antibiotic treatment.

1. Goossens HF, M.; Vander, S.R.; Elseviers, M. Outpatient antibiotics use in Europe and association with resistance: a cross-national database study. Lancet 2005; 365:579-587.
2. Centers for Disease Control and Prevention (CDC). Antibiotic Resistance Threats in the United States 2013.
3. World Health Organization. Antimicrobial resistance: global report on surveillance 2014.
4. Goossens H. Antibiotic consumption and link to resistance. Clin Microbiol Infect 2009; 15 Suppl 3:12-15.
5. European Centre for Disease Prevention and Control. Antimicrobial consumption. Annual epidemiological report for 2016. Stockholm, 2018.
6. Bronzwaer SLAM, Cars O, Buchholz U et al. A European study on the relationship between antimicrobial use and antimicrobial resistance. Emerging infectious diseases 2002; 8:278-282.
7. Bruns AH, Oosterheert JJ, Hak E, Hoepelman AI. Usefulness of consecutive C-reactive protein measurements in follow-up of severe community-acquired pneumonia. Eur Respir J 2008; 32:726-732.
8. Coelho L, Povoa P, Almeida E et al. Usefulness of C-reactive protein in monitoring the severe community-acquired pneumonia clinical course. Crit Care 2007; 11:R92.

Marketing and sales materials

QuikRead go wrCRP & wrCRP+Hb Brief Instructions (EN)

QuikRead go Family Brochure (EN)

QuikRead go Technical Specifications (EN)

Instructions for Fingertip Blood Collection (EN)

QuikRead go Control Information (EN)

Stories

Targeted antibiotic use in primary healthcare (EN)

Videos

QuikRead go wrCRP Test Procedure Video (EN)

Instructions for use

(For informative use only. Kindly always refer to the latest package insert in the kit.)

QuikRead go wrCRP IFU (FI, SE, NO, DK), 146521, 146522, 152634

QuikRead go wrCRP IFU (GB, DE, FR, IT), 146521, 146522, 152634

QuikRead go wrCRP IFU (NL, ES, EE, LI), 146521, 146522, 152634

QuikRead go wrCRP IFU (CZ, SK, HU, PL), 146521, 146522, 152634

QuikRead go CRP Controls IFU (GB, DE, FR, ES, IT, CZ, HU, PL, SK, NL, EE, LT, SE, NO, DK, FI), 153765, 153764, 153763

QuikRead go wrCRP Control IFU (GB, DE, FR, ES, IT, CZ, HU, PL, SK, SI, NL, EE, LT, SE, NO, DK, FI), 153038

QuikRead wrCRP Control High IFU (GB, DE, FR, ES, IT, CZ, HU, PL, SK, SI, NL, EE, LT, SE, NO, DK, FI), 153039

Ultrasensitive CRP Conrol IFU (GB, DE, FR, ES, IT, NL, CZ, SK, SI, SE, NO, DK, FI), 68257

Safety Data Sheet

QuikRead go wrCRP SDS (EN) 146521, 146522

QuikRead go CRP Control SDS (EN) 153764

QuikRead go CRP Control High SDS (EN) 153763

QuikRead go CRP Control Low SDS (EN) 153765

QuikRead go wrCRP Control SDS (EN) 153038

QuikRead go wrCRP Control High SDS (EN) 153039

Ultrasensitive CRP Control SDS (EN) 68257

I would like to start using the QuikRead go wrCRP tests. Which instrument software version I need on my QuikRead go instrument?

You should have the version 7.5.1.

I have updated my QuikRead go instrument into version 7.5.1 to start using the QuikRead go wrCRP test. However, now I noticed I have still some QuikRead go CRP kits in fridge. Can I use these kits still after the software update?

Yes, in addition to the QuikRead go wrCRP tests, you can use the QuikRead go CRP and QuikRead go CRP+Hb kits with the QuikRead go instrument software version 7.5.1.

I accidentally left a QuikRead go wrCRP kit at room temperature for a weekend. Can I still use it?

Yes, you can use the kit. The unopened kit can be stored at cool or room temperature (2 - 25 ºC) until the expiry date marked on the kit label. After the first opening of the kit components, the cuvettes can be kept at room temperature (18 - 25) for 3 months. The reagent caps for 6 months. See more information in the package insert.

What happens if I accidentally use the 20 µl capillaries with the QuikRead go wrCRP test?

It is important to use only the 10 µl capillaries with orange stripe, which are inside the QuikRead go wrCRP test kit. The 20 µl capillaries have a blue stripe and are to be used with QuikRead go CRP test only. The instrument measures the haematocrit value and above the upper limit (75%), it will not give results. If you dispense twice the amount of sample, the instrument thinks the haematocrit value is double what it actually is. The HCT correction is able to correct only those sample results, which have hematocrit below 37.5%.